key: cord-1004877-809mx2lh authors: Farias, Davi Felipe; Souza, Terezinha; Ribeiro Souza, Juliana Alves Costa; Vieira, Leonardo Rogério; Muniz, Marta Silva; Martins, Rafael Xavier; Gonçalves, Íris Flávia Sousa; Pereira, Eduardo Afonso Silva; Maia, Maria Eduarda Souza; Silva, Marília Guia Flor title: COVID‐19 Therapies in Brazil: Should We Be Concerned with the Impacts on Aquatic Wildlife? date: 2020-10-02 journal: Environ Toxicol Chem DOI: 10.1002/etc.4888 sha: 39a1951b2474daefc899181c31a07f84fc405fe3 doc_id: 1004877 cord_uid: 809mx2lh The use of unproven COVID‐19 drugs has seen a massive increase in recent months in Brazil. Chloroquine (CQ), hydroxychloroquine (HCQ) and ivermectin (IVM) are among the most politically promoted and sold drugs. As a result, an increased demand for these pharmaceuticals has been observed across the country with sales increase by more than 50% in comparison to 2019. In a country where only 46% of domestic wastewater is treated, what can we expect from the effects of these drugs and their metabolites on aquatic wildlife? The environmental fate and ecotoxicity data for IVM indicate varying degrees of toxicity to aquatic invertebrates and the potential to accumulate in several aquatic organisms. The CQ compound was classified as harmful to aquatic organisms and may cause long‐term adverse effects in the aquatic environment. As for HCQ, it has been tagged as posing insignificant environmental risks in the pre‐pandemic scenario despite its environmental persistence. Fragile Brazilian biomes, such as the Amazon (North region), Caatinga and coastal region of the Northeast and the Atlantic Rainforest (Southeast region) are of particular concern given the high incidence of COVID‐19 cases in these areas. The large‐scale use of unproven drugs in response to the pandemic may add undue weight to the increased volume of pharmaceuticals entering the environment, leaving the local biota vulnerable to the harmful effects of these contaminants. A nationwide coordinated response is urgently needed to monitor the levels and investigate the impacts of these emerging contaminants. This article is protected by copyright. All rights reserved. in comparison to 2019. In a country where only 46% of domestic wastewater is treated, what can we expect from the effects of these drugs and their metabolites on aquatic wildlife? The environmental fate and ecotoxicity data for IVM indicate varying degrees of toxicity to aquatic invertebrates and the potential to accumulate in several aquatic organisms. The CQ compound was classified as harmful to aquatic organisms and may cause long-term adverse effects in the aquatic environment. As for HCQ, it has been tagged as posing insignificant environmental risks in the pre-pandemic scenario despite its environmental persistence. Fragile Brazilian biomes, such as the Amazon (North region), Caatinga and coastal region of the Northeast and the Atlantic Rainforest (Southeast region) are of particular concern given the high incidence of COVID-19 cases in these areas. The large-scale use of unproven drugs in response to the pandemic may add undue weight to the increased volume of pharmaceuticals entering the environment, leaving the local biota vulnerable to the harmful effects of these contaminants. A nationwide coordinated response is urgently needed to monitor the levels and investigate the impacts of these emerging contaminants. Keywords: aquatic toxicology, contaminants of emerging concern, pharmaceuticals, risk assessment Brazil is currently the Latin American epicenter of the COVID-19 pandemic, whose impacts have permeated the economic, social, and healthcare spheres. Amidst its worst sanitary crisis, the country has also been struggling with anti-science political narratives that promote the widespread use of chloroquine (CQ) and hydroxychloroquine (HCQ) and more recently the antiparasitic ivermectin (IVM). As a result, an increased demand for these pharmaceuticals has been observed across the country with sales increase by more than 50% in comparison to 2019 (CFF 2020). This steep increase in the use of such drugs, however, may pose risks to Brazil's highly biodiverse biomes -an issue that overlaps with the country's precarious wastewater treatment situation. Data from 2018 indicated that almost half of the Brazilian population does not have access to sewage collection; the Northern and Northeast regions (historically at economic disadvantage) are particularly vulnerable since only 10.49% and 28.01% of their inhabitants have access to adequate sanitation ( Figure 1) . Nationwide, 46% of collected sewage is treated, but high treatment rates (above 80%) are observed in only 21 of the 100 largest cities (Instituto Trata Brasil 2019). Such poor sanitation conditions have detrimental effects on human health and the environment. Many contemporary pollutants are pharmaceuticals, which are concerning due to their toxicity to aquatic organisms, ever increasing amounts, and relative chemical stability. Organ damage, reproductive toxicity, hormonal disruption, behavioral changes, mutagenicity, and carcinogenicity are some of the reported effects of widely used drugs on various amphibian, fish, and invertebrate species (OECD 2019). In Brazil, pharmaceuticals are particularly important as emerging pollutants due to selfmedication, inappropriate disposal of unused or expired medications in the toilet or common garbage and the lack of efficient wastewater collection/ treatment to remove chemical wastes, as well as lack of regulations establishing environmental acceptable concentrations (Quadra et al. 2017) . A wide variety of pharmaceuticals for human or veterinary use (e.g. analgesics and anti-inflammatories, antibiotics, hormones, caffeine, etc.) and personal care products (triclosan) have already been found in Brazilian water bodies (mainly rivers, reservoirs, and potable water) (Quadra et al. 2017) . These water samples, mostly obtained from the Southeast region of Brazil, indicates the looming threats of these compounds since this region has the largest rate of sewage collection and treatment ( Figure 1) . Thus, with a massive increase in the use of CQ, HCQ and IVM in Brazil This article is protected by copyright. All rights reserved. and their likely entry into aquatic environments, what can we expect from the effects of these drugs and their metabolites on aquatic wildlife? Ivermectin is a macrocyclic lactone used worldwide to treat human and animal parasites such as scabies and ticks since the 1980s and its environmental effects are better understood than those of CQ and HCQ. Environmental fate studies on IVM have shown that this hydrophobic compound may persist in soil and sediment, as well as accumulate in various aquatic organisms leading to various degrees of toxicity, with larval instars of invertebrates being particularly vulnerable (Mesa et al. 2017 ). In turn, CQ and HCQ are aminoquinoline drugs widely used in the prevention and treatment of malaria despite the gradual reduction of their use in regions with reported resistant Plasmodium strains. HCQ is also used to treat rheumatoid arthritis and systemic lupus erythematosus. Despite the limited data on CQ toxicity to aquatic wildlife, Zurita et al. (2005) were able to classify this compound as "R52/53 Harmful to aquatic organisms and may cause long-term adverse effects in the aquatic environment". For HCQ, data on its environmental effects are even more scarce; the available information tagged this compound as an insignificant environmental risk in the pre-pandemic scenario despite its persistence (Health and Medical Care Administration -Region Stockholm 2015). In Brazil, efforts to identify and mitigate the effects of these drugs on ecosystems are compromised due to the absence of a robust regulatory framework for emerging contaminants. The current legislation sets limits for some herbicides and agricultural products in surface waters, but largely ignores pharmaceuticals. In the absence of regulations to establish monitoring practices or maximum contaminant levels for these Bubble sizes represent the number of confirmed COVID-19 cases (x100,000) registered until August 6, 2020 (The Center for Systems Science and Engineering (CSSE) at Johns Hopkins University database). Coronavirus COVID-19 (2019-nCoV) Levantamento mostra como o medo da Covid-19 impactou venda de medicamentos. Brasília: Conselho Federal de Farmácia Health and Medical Care Administration -Region Stockholm Esgoto. São Paulo: Instituto Trata Brasil Aquatic toxicity of ivermectin in cattle dung assessed using microcosms Pharmaceutical Residues in Freshwater Do pharmaceuticals reach and affect the aquatic ecosystems in Brazil? A critical review of current studies in a developing country Ecotoxicological evaluation of the antimalarial drug chloroquine